The treatment known as RECO did not significantly reduce the severity of organ failure as measured by the mean daily SOFA (sequential organ failure assessment) score from the start of the study to day 4 in patients with septic shock.

Larger, adequately powered trials are needed to determine if RECO may have delayed benefits.

The study included 180 patients, of whom 178 completed the trial (87 in the RECO group and 91 in the control group) and were included in the intention-to-treat analysis (60.7% were men, with a median age of 68 [range 59-75] years).

The mean daily SOFA score was not significantly different between the RECO group and the control group (7.2 points [range 5.2-10.7] versus 7.6 points [range 4.9-10.7], respectively; p = 0.919).

Within 90 days of the study, 27.6% of the RECO group and 39.6% of the control group had died (Log-rank test, p = 0.10; adjusted hazard ratio 0.59, 95% CI, 0.35 to 0.99; p = 0.049).

Read More